Comprehensive Treatment Algorithms of the Swiss Peritoneal Cancer Group for Peritoneal Cancer of Gastrointestinal Origin.

Adamina, Michel; Warlaumont, Maxime; Berger, Martin D; Däster, Silvio; Delaloye, Raphaël; Digklia, Antonia; Gloor, Beat; Fritsch, Ralph; Köberle, Dieter; Koessler, Thibaud; Lehmann, Kuno; Müller, Phaedra; Peterli, Ralph; Ris, Frédéric; Steffen, Thomas; Weisshaupt, Christian Stefan; Hübner, Martin (2022). Comprehensive Treatment Algorithms of the Swiss Peritoneal Cancer Group for Peritoneal Cancer of Gastrointestinal Origin. Cancers, 14(17) MDPI AG 10.3390/cancers14174275

cancers-14-04275-v4.pdf - Published Version
Available under License Creative Commons: Attribution (CC-BY).

Download (2MB) | Preview

Peritoneal cancer (PC) is a dire finding, yet in selected patients, long-term survival is possible. Complete cytoreductive surgery (CRS) together with combination immunochemotherapy is essential to achieve cure. Hyperthermic intraperitoneal chemotherapy (HIPEC) and pressurized intraperitoneal aerosol chemotherapy (PIPAC) are increasingly added to the multimodal treatment. The Swiss Peritoneal Cancer Group (SPCG) is an interdisciplinary group of expert clinicians. It has developed comprehensive treatment algorithms for patients with PC from pseudomyxoma peritonei, peritoneal mesothelioma, gastric, and colorectal origin. They include multimodal neoadjuvant treatment, surgical resection, and palliative care. The indication for and results of CRS HIPEC and PIPAC are discussed in light of the current literature. Institutional volume and clinical expertise required to achieve best outcomes are underlined, while inclusion of patients considered for CRS HIPEC and PIPAC in a clinical registry is strongly advised. The present recommendations are in line with current international guidelines and provide the first comprehensive treatment proposal for patients with PC including intraperitoneal chemotherapy. The SPCG comprehensive treatment algorithms provide evidence-based guidance for the multimodal care of patients with PC of gastrointestinal origin that were endorsed by all Swiss clinicians routinely involved in the multimodal care of these challenging patients.

Item Type:

Journal Article (Review Article)


04 Faculty of Medicine > Department of Haematology, Oncology, Infectious Diseases, Laboratory Medicine and Hospital Pharmacy (DOLS) > Clinic of Medical Oncology
04 Faculty of Medicine > Department of Gastro-intestinal, Liver and Lung Disorders (DMLL) > Clinic of Visceral Surgery and Medicine > Visceral Surgery

UniBE Contributor:

Berger, Martin Dave; Gloor, Beat and Köberle, Dieter


600 Technology > 610 Medicine & health








Pubmed Import

Date Deposited:

13 Sep 2022 13:17

Last Modified:

05 Dec 2022 16:24

Publisher DOI:


PubMed ID:


Uncontrolled Keywords:

HIPEC PIPAC cytoreductive surgery gastrointestinal cancer hyperthermic intraperitoneal chemotherapy peritoneal carcinomatosis pressurized intraperitoneal chemotherapy




Actions (login required)

Edit item Edit item
Provide Feedback